Related Experiment Video

Updated: May 21, 2025

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.8K

The Interplay Of The Angiotensin Receptor Blockers And Haematological Abnormalities: Insights And Implications

Ghada M Ahmed1, Fawaz A Alassaf2, Mohammed Najam Abed3

  • 1Nineveh health directorate, Mosul, Nineveh province, Iraq.

Journal of Ayub Medical College, Abbottabad : JAMC
|March 23, 2025
PubMed

Insights

Angiotensin receptor blockers (ARBs) may cause anemia by inhibiting erythropoiesis. Dose adjustment or discontinuation of ARBs might correct this hematological abnormality, depending on clinical context.

Area of Science:

  • Pharmacology
  • Nephrology
  • Cardiology

Background:

  • Angiotensin receptor blockers (ARBs) are increasingly used for hypertension, congestive heart failure, and diabetes due to their organ-protective effects.
  • Conflicting evidence exists regarding the association between ARBs and hematological abnormalities.
  • Erythropoiesis, the production of red blood cells, is influenced by the renin-angiotensin system.

Purpose of the Study:

  • To investigate the relationship between angiotensin receptor blockers (ARBs) and hematological abnormalities, specifically anemia.
  • To clarify the impact of ARBs on erythropoiesis and hematocrit levels.

Main Methods:

  • A comprehensive literature search was conducted using PubMed, Cochrane Library, and Google Scholar.
  • Included studies were published in English before July 2023.
  • Data from selected studies were analyzed to determine the effects of ARBs on hematological parameters.

Main Results:

  • Angiotensin II plays a crucial role in stimulating erythropoiesis.
  • Inhibition of angiotensin II by ARBs can lead to decreased hematocrit levels.
  • This reduction in hematocrit can result in anemia.

Conclusions:

  • Angiotensin receptor blockers (ARBs) can potentially cause anemia by interfering with erythropoiesis.
  • Dose reduction or cessation of ARBs may be considered for managing ARB-induced anemia.
  • Clinical judgment is essential when deciding on management strategies for anemia in patients taking ARBs.

Keywords:
Angiotensin receptor blockers; Haematological abnormalities; Anaemia

More Related Videos

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

37.1K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.6K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
561
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
466
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
436
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
119